Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Format: Artigo
Idioma:Inglês
Publicat: MDPI AG 2020-03-01
Col·lecció:International Journal of Molecular Sciences
Matèries:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Accés en línia:https://www.mdpi.com/1422-0067/21/7/2275
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars